The Company intends to raise funds by issuing 33,00,000 Warrants and 6,75,000 Equity Shares on a preferential basis at a price of Rs. 55.00 per share to the identified allottees subject ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 3.7 pts more than Nifty Microcap 250 and 3.7 pts more than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Eiko Lifesciences' board has approved acquiring 51% equity (71,71,950 shares) in SSM Formulations Private Limited, a pharmaceutical formulations manufacturer, for a cash consideration of Rs. 18 crore. Post-acquisition, SSM Formulations will become a subsidiary of Eiko, enabling forward integration into pharma formulations and expanding its API and specialty chemicals portfolio. SSM Formulations reported turnover of Rs. 27.65 crore in FY25, down from Rs. 50.82 crore in FY23, indicating declining revenue. To fund growth, the board also approved a preferential issue of 33 lakh warrants and 6.75 lakh equity shares at Rs. 55 each to promoters, promoter group and non-promoters, mobilising up to Rs. 21.86 crore in total. An EGM has been scheduled on January 7, 2026 to seek shareholder approval.
Existing shareholders will face dilution from the preferential allotment, though promoter group participation (over 90% of warrants and shares) signals insider confidence. The pharma acquisition diversifies revenue but inherits a target with declining turnover, so execution and synergy realisation will be key for future stock performance.